公开(公告)号：US20190298809A1

公开(公告)日：2019-10-03

申请号：US16412192

申请日：2019-05-14

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA ,  PHOENIX TISSUE REPAIR, INC.

Inventor： Mei Chen ,  David Woodley ,  Mark de Souza

IPC: A61K38/39

Abstract: The present disclosure provides methods of treating epidermolysis bullosa, and/or preventing, preventing the progression of, or delaying the onset of one or more symptom associated with scarring, e.g., of blisters, in subjects with epidermolysis bullosa through chronic systemic administration of collagen 7.

公开(公告)号：US10273294B2

公开(公告)日：2019-04-30

申请号：US14932908

申请日：2015-11-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  C12N15/113

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1α-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP (SEQ ID NO: 1) in Hsp90α or VKHFSVEGQ (SEQ ID NO: 2) in Hsp90α.

公开(公告)号：US11359008B2

公开(公告)日：2022-06-14

申请号：US16375661

申请日：2019-04-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/28 ,  C12N15/113 ,  C12N15/13

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α.

公开(公告)号：US11261235B2

公开(公告)日：2022-03-01

申请号：US16891413

申请日：2020-06-03

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： Mei Chen ,  David Woodley

IPC: A61K38/39 ,  C07K14/78 ,  A61K31/70

Abstract: The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, miniC7 protein, variants thereof or small growth factors to achieve synergistic healing effect.

公开(公告)号：US20160053003A1

公开(公告)日：2016-02-25

申请号：US14932908

申请日：2015-11-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  C12N15/113

CPC classification number: C07K16/18 ,  A61K39/39558 ,  C07K16/2857 ,  C07K2317/34 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2330/50

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α.

Abstract translation: 本文描述了包括特异性结合Hsp90α的单克隆抗体的组合物及其用于治疗HIF-1a过表达癌症的方法。 在一些实施方案中，癌症是乳腺癌或肺癌。 单克隆抗体结合Hsp90α中的表位TKPIWTRNP或Hsp90α中的VKHFSVEGQ。